Title
Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis.

Permalink
https://escholarship.org/uc/item/1w38t06r

Journal
Clinical case reports, 6(9)

ISSN
2050-0904

Authors
Otani, Iris M
Carroll, Ryan W
Yager, Phoebe
et al.

Publication Date
2018-09-01

DOI
10.1002/ccr3.1607

Peer reviewed
INTRODUCTION

Diffuse cutaneous mastocytosis (DCM) is a rare and potentially fatal form of cutaneous mastocytosis that is associated with significant mast cell (MC) infiltration of the skin.1-3 As most cutaneous mastocytosis cases are not associated with significant morbidity or mortality, it is under-recognized that the DCM type of cutaneous mastocytosis is associated with fatal complications.1,4 DCM is characterized by diffuse dense infiltrates of MCs in the dermis, and this high MC burden can result in significant amounts of MC mediator release leading to systemic reactions that can be severe and even fatal.5-8 Given the risk for life-threatening complications, it is important to consider
DCM in pediatric patients with a concerning skin examination (skin with “peau d’orange” appearance, hyper-pigmentation, positive Darier’s sign). A serum tryptase level is an objective screening tool for MC disorders. Early diagnosis can allow physicians and patients to avoid MC degranulation triggers and initiate prophylactic therapy to decrease the risk of MC activation, minimizing complications and improving clinical outcomes.

This case illustrates the clinical course and potentially fatal complications of DCM, and the effective treatment options that are currently available. This particular case is also novel in that it is, to our knowledge, the first reported case of a somatic K509I KIT mutation and the first reported case of concomitant mastocytosis and tuberous sclerosis.

2 | CASE

A four-month-old male infant was referred to an emergency department from his pediatrician’s office with fever, irritability, and bullous skin lesions covering a third of the body surface area without mucosal involvement. In the emergency department, he decompensated acutely and developed cardiac arrest requiring cardiopulmonary resuscitation and hemodynamic support with dobutamine, dopamine, milrinone, and norepinephrine. He required mechanical ventilation for acute respiratory distress syndrome and right ventricular heart failure with evidence of pulmonary hypertension, and emergent hemodialysis for acute kidney failure. Due to continued concerns for disseminated infection, he received vancomycin, ceftriaxone, acyclovir, and clindamycin. He developed disseminated intravascular coagulopathy and received multiple transfusions of packed red blood cells, fresh frozen plasma, and cryoprecipitate.

Skin biopsy of one of the abdominal bullae showed dense dermal infiltrate of MCs with subepidermal vesiculation consistent with a diagnosis of mastocytosis (Figure 1A). Immunohistochemistry for KIT (CD117) showed diffuse positivity of the dermal infiltrate, further supporting the diagnosis (Figure 1B). Direct immunofluorescence was negative for fibrinogen, C3, and immunoglobulins G, M, and A.

4 | TREATMENT

The patient was transferred to our institution for further care. He remained critically ill in the pediatric intensive care unit for a total of 31 days. Initial skin examination showed diffuse blisters and bullae containing serous fluid over the chest, abdomen, back, neck, and posterior scalp (Figure 2A). A total serum tryptase level were 162 nanograms/milliliter (ng/mL), (normal range <11.4 ng/mL). Mature β-tryptase was <1 ng/mL (normal range <1 ng/mL). Significance of these laboratory results discussed below.

Treatment was initiated with systemic steroids (methylprednisolone 6.3 milligrams (mg) intravenously (IV) every 6 hours), H1-antihistamine and H2-antihistamines (diphenhydramine 6.25 mg IV every 6 hours and famotidine 3 mg IV every 24 hours), leukotriene antagonist (montelukast 4 mg per nasogastric tube every 24 hours), proton pump inhibitor (esomeprazole 3 mg IV every 12 hours), and MC stabilizer (cromolyn sodium enteral concentrate 30 mg per nasogastric tube every 6 hours). Precautions were taken to avoid MC degranulation triggers: physical stimuli—friction of skin lesions, heat, cold, pressure, and drugs with MC degranulation potential including vancomycin and radiocontrast media.

5 | FURTHER INVESTIGATIONS AND FINAL DIAGNOSIS

Further investigations were performed to investigate the extent of MC involvement. Bone marrow (BM) aspirate smears showed normal MC numbers with normal MC morphology without aberrant CD25+ MCs. BM flow cytometry did not show any evidence of abnormal CD117+/CD25+ MCs. The percentage of CD25+/CD117dim+/CD2dim+/CD3(-)/CD34(-) BM MCs detected by flow cytometry was 0.03%. Gastrointestinal (GI) biopsies of the esophagus, stomach antrum, and duodenum did not show increased MC numbers or abnormal MC morphology. The absence of systemic involvement on available BM and GI studies supported a diagnosis of cutaneous mastocytosis, subtype diffuse cutaneous mastocytosis (DCM).
KIT (tyrosine kinase) mutational analysis performed to guide cytoreductive therapy options with tyrosine kinase inhibitors was positive for K509I mutation on skin biopsy and peripheral blood at a level consistent with a somatic mutation (~10%). KIT mutational analysis was performed by extracting DNA from bone marrow aspirate and paraffin-embedded skin tissue and screened for mutations by Sanger sequencing and high-resolution melting curve analysis.

Patient has been stable on follow-up to date 3 years after initial presentation with DCM management. However, as the K509I mutation is also associated with well-differentiated systemic mastocytosis, if patient develops new symptoms in the future, BM core biopsy may be needed to definitively rule out well-differentiated systemic mastocytosis.12

Further studies were also performed to investigate the subtle clinical seizures that started during hospitalization. Electroencephalography showed evidence of status epilepticus, and brain MRI/MRA showed findings suggestive of hypoperfusion and excitotoxic injury with the additional incidental detection of subependymal nodules and cortical tubers concerning for TS complex. Genetic sequencing revealed a heterozygous c.3397 + 5 G>A splice site mutation in the TSC2 gene, supporting a diagnosis of TS.

6 | OUTCOME AND FOLLOW-UP

With continuation of the above treatment and cautious avoidance of MC triggers, total serum tryptase levels decreased (Figure 3) and skin continued to improve, with re-epithelialization and only scattered small focal erosions at sites of previous bullae remaining 2 weeks after admission to our institution (Figure 2B). Imatinib was considered but deferred given improvement with the above treatment. At time of retro-transfer to the referring hospital 1 month after presentation, neurologic examination was notable for an awake, alert infant with development of spasticity in all extremities, and the dermatologic examination was notable for re-epithelialization and slightly thickened skin with a yellowish hue (Figure 2C).

7 | DISCUSSION

Diffuse cutaneous mastocytosis is a form of cutaneous mastocytosis that typically presents with cutaneous manifestations at birth or early infancy.2,13 DCM arises from a clonal MC expansion and is often due to a gain-of-function mutation in KIT, which encodes the receptor for stem cell factor (SCF), a potent MC growth factor.2,13 Degranulation of cutaneous MCs release MC mediators into the systemic circulation and cause systemic symptoms.6,14-16

Skin examination is key to differentiate DCM from other benign forms of cutaneous mastocytosis and other bullous dermatological conditions. In DCM, the skin can develop a thickened, leathery appearance with yellowish discoloration, accentuation of hair follicles, and increased folding (“peau d’orange”).14 Blistering, flushing, erythema, edema, pruritus, and dermatographism can also be seen.14 Darier’s sign, elicited by gently stroking
FIGURE 2  A, Day 1 at our institution. Multiple tense vesicles and bullae filled with serous or hemorrhagic fluid and few large flaccid bullae over the abdomen. Multiple clean-based large erosions over the back. B, Day 5 at our institution. Chest and abdomen with near complete reattached epidermis, back with healing clean-based erosions in various stages of re-epithelialization. C, Day of transfer from our institution back to outside hospital near parents’ home (day 31 at our institution). Erythematous patches at sites of healed lesions over the torso.

FIGURE 3  Tryptase levels during hospitalization.
the affected skin, is often demonstrated.14,17 Darier’s sign, although an important screening tool for mastocytosis, should not be elicited in children with cutaneous mastocytosis presenting with extensive cutaneous involvement. This is because skin manipulation in this situation can trigger life-threatening massive mast cell mediator release associated with extensive cutaneous involvement.7,10

A total serum tryptase level is a simple and effective test to screen for mast cell disorders. An elevated total serum tryptase level indicates an aberration in MC function and/or number and should prompt an urgent referral to an allergist.6,10 Total tryptase levels can be elevated due to elevations of the inactive protryptase form or the active β-tryptase form.18 Measuring a β-tryptase level identifies which form is elevated. A normal β-tryptase level equates to elevation of inactive protryptase and a baseline higher MC burden.6,10 An elevated β-tryptase level indicates that MCs were recently activated and released β-tryptase (the half-life of tryptase is on the order of two to four hours).18

Our patient had an elevated total serum tryptase level and a normal β-tryptase level. Most likely, the β-tryptase level would have been elevated if it was checked in the two to four hours after presentation (it was checked more than 24 hours after the initial presentation). Acute elevation of beta-tryptase is a risk factor for developing DIC, which occurred in our patient, as active beta-tryptase can cleave fibrinogen to fibrin.19 The normal β-tryptase level meant that the total serum tryptase level consisted of predominantly inactive protryptase reflecting an increased risk for severe MC activation.6,10

Serum tryptase is also one of the key factors that can help identify children with cutaneous mastocytosis at risk for fatal or near-fatal mast cell activation events. Previous reports of fatal bullous mastocytosis cases suggest that neonatal onset of cutaneous lesions, extensive bullous cutaneous involvement,7,15 and symptoms of vasodilation and flushing7 are common clinical factors associated with fatal mast cell activation events. An analysis of 111 children with cutaneous mastocytosis found that extensive cutaneous disease involving >90% of body surface area and serum tryptase >15.5 μg/L are associated with severe symptoms requiring hospitalization.10 The same study found that serum tryptase >30.8 μg/L is associated with severe symptoms requiring management in an ICU.10

Early consideration of DCM prompting allergy referral is crucial as early diagnosis allows for avoidance of MC triggers that lead to potentially fatal MC activation. Patients with DCM are particularly prone to MC triggers due to skin manipulation, as perivascular MC infiltrates are present even in areas of skin that appear normal on the surface.3,16 Even precipitous temperature changes and routine vaccination can cause severe generalized blisters.16,21 Therefore, patients are likely to suffer severe reactions in response to MC triggers ubiquitous in daily life unless they are educated regarding conscious avoidance of MC triggers.

In addition to avoidance of MC triggers, early diagnosis allows for initiation of effective prophylaxis. Prophylactic therapy with long-acting antihistamines is the mainstay of treatment.16,22 Cromolyn sodium, a MC stabilizer, can be administered via an enteral route to treat gastrointestinal symptoms.23 Leukotriene antagonists can be efficacious in bullous mastocytosis.24 Glucocorticoids can be used in severe cases.5,25 Symptom remission has been reported for 2 months to years after PUVA (psoralen, which makes the skin more sensitive to UV light, and ultraviolet A) therapy.26-28

Furthermore, preceding awareness of a DCM diagnosis can improve treatment in cases where patients experience a life-threatening flare despite MC trigger avoidance and prophylactic therapies. Epinephrine is the vasopressor of choice when these patients develop cardiovascular collapse, as it can stabilize MCs and prevent further degranulation.2 Medications with known MC degranulation potential (including vancomycin and general anesthetics and radiographic contrast media) should only be used after careful consideration and discussion with an allergy specialist.2,16

This case also has unique genetic features. To the best of our knowledge, our case is the first report of a somatic K509I KIT mutation. The majority of KIT mutations are somatic,2 with D816V (valine for aspartate in codon 816 [exon 17], Asp816Val) being the most commonly seen KIT mutation in mastocytosis.29 There have been three reports of familial mastocytosis due to germline but not somatic K509I mutation and one report of an individual with a de novo germline mutation.12,30-32

In addition to the somatic K509I KIT mutation, our patient had a mutation in the TSC2 gene. The TS complex causes benign solid organ tumors and is not known to affect immune cells (including mast cells).33 Although our patient had a specific mutation that accounted for the MC clonality causing his DCM, it is interesting to note in the context of our patient’s particularly severe and life-threatening initial presentation that the TSC1 and TSC2 protein-complex is a tumor suppressor and that mastocytosis (cutaneous and systemic) is a clonal disorder of mast cells.3,33 Literature review did not reveal other published reports describing a link between TS and mastocytosis and possible associations between this KIT mutation and TSC2 mutation remain conjecture.

ACKNOWLEDGMENTS

We would like to acknowledge Dr. Carl Kirsch for critical reading of this manuscript. We thank the patient and the
patient’s family for their verbal and written permission to report this case to the medical community.

CONFLICTS OF INTEREST
The authors have no conflicts of interest relevant to this article to disclose.

AUTHORSHIP
IO and JW: drafted the initial manuscript and revised the manuscript to its final draft. IO: provided Figure 3. RC, SM, and PY: reviewed and revised the manuscript focusing on details of the critical care provided. DK: reviewed and revised the manuscript focusing on details of the dermatological exam and provided Figure 2. CA, JLH, and MC: reviewed and revised the manuscript focusing on details of mastocytosis. JLH: provided Figure 1. All authors approved the final manuscript as submitted.

ORCID
Iris M. Otani http://orcid.org/0000-0003-4496-7988

REFERENCES
1. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35-45.
2. Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep. 2013;13:693-701.
3. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am. 2014;34:207-218.
4. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677-690.
5. Heide R, Zuidema E, Beishuizen A, et al. Clinical aspects of diffuse cutaneous mastocytosis in children: two variants. Dermatology. 2009;219:309-315.
6. Lange M, Niedoszytko M, Renke J, Gleń J, Niedoszytko B. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol. 2013;27:97-102.
7. Murphy M, Walsh D, Drumn B, Watson R. Bullous mastocytosis: a fatal outcome. Pediatr Dermatol. 1999;16:452-455.
8. Poterack CD, Sheth KJ, Henry DP, Eisenberg C. Shock in an infant with bullous mastocytosis. Pediatr Dermatol. 1989;6:122-125.
9. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226-232.
10. Alvarez-Twose I, Vaño-Galván S, Sánchez-Muñoz L, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67:813-821.
11. Polk RE, Israel D, Wang J, Venitz J, Miller J, Stotka J. Vancomycin Skin Tests and Prediction of “Red Man Syndrome” in Healthy Volunteers. Antimicrob Agents Chemother. 1993;37:2139-2143.
12. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137:168-178.e1.
13. Galli SJ, Grimaldi A, Tsai M. Regulators of Immunity. Nat Rev Immunol. 2008;8:478-486.
14. Hannaford R, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol. 2001;42:15-21.
15. Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003;48:508-516.
16. Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets. 2006;5:61-77.
17. Flageul B. Cutaneous mastocytosis. Rev Prat. 2006;56:1745-1751.
18. Caughey GH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol. 2006;117:1411-1414.
19. Prieto-García A, Zheng D, Adachi R, et al. Mast cell restricted mouse and human tryptase-heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen. J Biol Chem. 2012;287:7834-7844.
20. Orkin M, Good RA, Clawson CC, Fisher I, Windhorst DB. Bullous Mastocytosis. Arch Dermatol. 1970;101:547.
21. Bankova LG, Walter JE, Iyengar SR, Lorenzo ME, Hornick JL, Castells MC. Generalized Bullous Eruption after Routine Vaccination in a Child with Diffuse Cutaneous Mastocytosis. J Allergy Clin Immunol Pract. 2013;1:94-96.
22. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-453.
23. Edwards AM, Capkova S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep. 2011;2011:bcr0220113910.
24. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med. 2004;350:735-736.
25. Has C, Misery L, David L, Cambazard F. Recurring staphylococcal scalded skin syndrome-like bullous mastocytosis: the utility of cytodiagnosis and the rapid regression with steroids. Pediatr Dermatol. 2002;19:220-223.
26. Wolff K. Treatment of cutaneous mastocytosis. Int Arch Allergy Immunol. 2002;127:156-159.
27. Huang QS, Zhuo FH, Zeng XY. Diffuse cutaneous mastocytosis. J Clin Dermatol. 2012;41:131-132.
28. Smith ML, Orton PW, Chu H, Weston WL. Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol. 1990;7:251-255.
activating c-KIT mutations. *J Invest Dermatol.* 2010;130:804-815.

30. de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. *Leuk Res.* 2014;38:1245-1251.

31. Chan EC, Bai Y, Kirshenbaum AS, et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. *J Allergy Clin Immunol.* 2014;134:178-187. e1.

32. Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis - In vitro and in vivo responsiveness to imatinib therapy. *Leuk Res.* 2006;30:373-378.

33. Garg K, Karnezis AN, Rabban JT. Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation. *Pathology.* 2018;50:238-256.

How to cite this article: Otani IM, Carroll RW, Yager P, et al. Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis. *Clin Case Rep.* 2018;6:1834–1840. [https://doi.org/10.1002/ccr3.1607]